Published Date: 26 Apr 2023
Psilocybin, LSD, and MDMA are psychedelic drugs that may significantly lessen the severity of depression and anxiety symptoms in people with advanced cancer.
Read Full Newsargenx's efgartigimod-alfa therapy was approved for seropositive generalized myasthenia gravis in 2021.
Early initiation of opicapone significantly reduces OFF time and enhances ON time in patients with recently diagnosed Parkinson's disease, improving overall treatment outcomes.
The FDA requested the full data from the phase 3 HOPE-3 study as part of its review of the biologics license application for deramiocel, which Capricor plans to submit in February 2026.
A five-year analysis from the National RLS Opioid Registry found that most patients with dopamine agonist augmented restless legs syndrome maintained stable, low-dose opioid therapy with sustained symptom control.
Personalized Care Improvements Identified for Older Patients with Skin Cancer
New Findings on Acne Incidence in Transgender Individuals, With Howa Yeung, MD, MSc
What to Expect at the 2026 Maui Derm Conference
1.
The Higher the Disability Burden From Disease, the Higher the Suicide Risk
2.
Win for Perioperative Durvalumab in Muscle-Invasive Bladder Cancer
3.
In breast cancer patients with nodes positive, preoperative hydroxyprogesterone may enhance disease-free survival.
4.
recognizing the mechanism by which the replication of the host cell is outperformed by the skin cancer virus.
5.
Preferred and Actual Location of Death Often Don't Match for Young Cancer Patients
1.
Targeted Approaches to Breast Cancer Liver Metastases: Surgery, Ablation, and Survival Insights
2.
What Is Gastrinoma? Understanding This Rare Tumor and Its Treatment Options
3.
Subarachnoid Hemorrhage: Emerging Insights into Pathophysiology and Future Management
4.
Landmark Medical Oncology Trials Redefining Early Breast Cancer Management
5.
Unveiling the Mystery of Castleman's Disease: A Journey to Better Health
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
2.
Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II
3.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
4.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
5.
From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation